Matches in SemOpenAlex for { <https://semopenalex.org/work/W2012126103> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- W2012126103 endingPage "134" @default.
- W2012126103 startingPage "124" @default.
- W2012126103 abstract "In the present study we investigated the effectiveness of 14, 15 and 18 nucleotide antisense phosphorothioate oligonucleotides (S-ODNs) directed to four different regions of the published mdr-1 gene sequence to reduce the level of mdr-1 gene product (p170, P-glycoprotein) and its function in the over-expressing cell lines LoVoDxR, S180DxR and KBChR8–5. The highest efficiency in reduction of multiple drug resistance was obtained at a concentration of 2 μM. In proliferation assays a growth reduction of 50% was observed after exposure of doxorubicin-resistant cells to S-ODN3. p170 protein expression of the resistant cell line LoVoDxR was reduced to the level of the sensitive cell line LoVo as shown by Western blot analysis. S-ODN3 reduced the ID50 of the two human cell lines up to 60% (LoVoDxR) and 21% (KBChR8–5), respectively, but showed no effect in the murine cell line S180DxR. In contrast, S-ODN1 was most effective in the murine system (67% reduction of the ID50), less effective in LoVoDxR (34%) and exhibited no effect in cell line KBChR8–5. Based on the results with the antisense oligonucleotides, a ribozyme directed against the mRNA target region of S-ODN3 was designed. This ribozyme was able to reduce the mdr-1 mRNA in total RNA preparations from cell line LoVoDxR up to 80% after an incubation time of 6 h in the presence of 10 mM MgCI2 at pH 7.5. A modified ribozyme was investigated in cell culture and reduced chemo-resistance of the resistant cell line LoVoDxR and ex vivo cultured blasts of acute myelold leukemia patients up to 50%." @default.
- W2012126103 created "2016-06-24" @default.
- W2012126103 creator A5007980662 @default.
- W2012126103 creator A5033935778 @default.
- W2012126103 creator A5061380659 @default.
- W2012126103 creator A5073076171 @default.
- W2012126103 creator A5075097465 @default.
- W2012126103 creator A5082167450 @default.
- W2012126103 creator A5089627681 @default.
- W2012126103 date "1995-02-01" @default.
- W2012126103 modified "2023-10-17" @default.
- W2012126103 title "Reversal of multiple drug resistance in vitro by phosphorothioate oligonucleotides and ribozymes" @default.
- W2012126103 doi "https://doi.org/10.1097/00001813-199502000-00015" @default.
- W2012126103 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7756675" @default.
- W2012126103 hasPublicationYear "1995" @default.
- W2012126103 type Work @default.
- W2012126103 sameAs 2012126103 @default.
- W2012126103 citedByCount "35" @default.
- W2012126103 countsByYear W20121261032012 @default.
- W2012126103 crossrefType "journal-article" @default.
- W2012126103 hasAuthorship W2012126103A5007980662 @default.
- W2012126103 hasAuthorship W2012126103A5033935778 @default.
- W2012126103 hasAuthorship W2012126103A5061380659 @default.
- W2012126103 hasAuthorship W2012126103A5073076171 @default.
- W2012126103 hasAuthorship W2012126103A5075097465 @default.
- W2012126103 hasAuthorship W2012126103A5082167450 @default.
- W2012126103 hasAuthorship W2012126103A5089627681 @default.
- W2012126103 hasConcept C104317684 @default.
- W2012126103 hasConcept C105580179 @default.
- W2012126103 hasConcept C129312508 @default.
- W2012126103 hasConcept C1491633281 @default.
- W2012126103 hasConcept C150194340 @default.
- W2012126103 hasConcept C153911025 @default.
- W2012126103 hasConcept C185592680 @default.
- W2012126103 hasConcept C202751555 @default.
- W2012126103 hasConcept C54355233 @default.
- W2012126103 hasConcept C55493867 @default.
- W2012126103 hasConcept C62112901 @default.
- W2012126103 hasConcept C67705224 @default.
- W2012126103 hasConcept C76346623 @default.
- W2012126103 hasConcept C81885089 @default.
- W2012126103 hasConcept C86803240 @default.
- W2012126103 hasConceptScore W2012126103C104317684 @default.
- W2012126103 hasConceptScore W2012126103C105580179 @default.
- W2012126103 hasConceptScore W2012126103C129312508 @default.
- W2012126103 hasConceptScore W2012126103C1491633281 @default.
- W2012126103 hasConceptScore W2012126103C150194340 @default.
- W2012126103 hasConceptScore W2012126103C153911025 @default.
- W2012126103 hasConceptScore W2012126103C185592680 @default.
- W2012126103 hasConceptScore W2012126103C202751555 @default.
- W2012126103 hasConceptScore W2012126103C54355233 @default.
- W2012126103 hasConceptScore W2012126103C55493867 @default.
- W2012126103 hasConceptScore W2012126103C62112901 @default.
- W2012126103 hasConceptScore W2012126103C67705224 @default.
- W2012126103 hasConceptScore W2012126103C76346623 @default.
- W2012126103 hasConceptScore W2012126103C81885089 @default.
- W2012126103 hasConceptScore W2012126103C86803240 @default.
- W2012126103 hasIssue "1" @default.
- W2012126103 hasLocation W20121261031 @default.
- W2012126103 hasLocation W20121261032 @default.
- W2012126103 hasOpenAccess W2012126103 @default.
- W2012126103 hasPrimaryLocation W20121261031 @default.
- W2012126103 hasRelatedWork W1569484918 @default.
- W2012126103 hasRelatedWork W1816037677 @default.
- W2012126103 hasRelatedWork W1996962471 @default.
- W2012126103 hasRelatedWork W2018094551 @default.
- W2012126103 hasRelatedWork W2090309653 @default.
- W2012126103 hasRelatedWork W2328381633 @default.
- W2012126103 hasRelatedWork W2357085341 @default.
- W2012126103 hasRelatedWork W2374922459 @default.
- W2012126103 hasRelatedWork W2386840998 @default.
- W2012126103 hasRelatedWork W2982232056 @default.
- W2012126103 hasVolume "6" @default.
- W2012126103 isParatext "false" @default.
- W2012126103 isRetracted "false" @default.
- W2012126103 magId "2012126103" @default.
- W2012126103 workType "article" @default.